Please select the option that best describes you:

Would you consider adding atezolizumab to a different chemotherapy/platinum-doublet backbone from the IMpower 133 trial for a new ES-SCLC patient?   

Would you consider adding atezolizumab to a cisplatin/irinotecan regimen, or cisplatin instead of carboplatin?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Florida Hospital Cancer Institute
I agree with @James Stevenson. Without safety data...
Medical Oncologist at Orange Reg Medcl Ctr
I agree.
Medical Oncologist at University of Virginia
I agree as well.
Sign in or Register to read more